A Computational Systems Biology Approach for Identifying Candidate Drugs for Repositioning for Cardiovascular Disease
We report an in silico method to screen for receptors or pathways that could be targeted to elicit beneficial transcriptional changes in a cellular model of a disease of interest. In our method, we integrate: (1) a dataset of transcriptome responses of a cell line to a panel of drugs; (2) two sets of genes for the disease; and (3) mappings between drugs and the receptors or pathways that they target. We carried out a gene set enrichment analysis (GSEA) test for each of the two gene sets against a list of genes ordered by fold-change in response to a drug in a relevant cell line (HL60), with the overall score for a drug being the difference of the two enrichment scores. Next, we applied GSEA for drug targets based on drugs that have been ranked by their differential enrichment scores. The method ranks drugs by the degree of anti-correlation of their gene-level transcriptional effects on the cell line with the genes in the disease gene sets. We applied the method to data from (1) CMap 2.0; (2) gene sets from two transcriptome profiling studies of atherosclerosis; and (3) a combined dataset of drug/target information. Our analysis recapitulated known targets related to CVD (e.g., PPARγ; HMG-CoA reductase, HDACs) and novel targets (e.g., amine oxidase A, δ-opioid receptor). We conclude that combining disease-associated gene sets, drug-transcriptome-responses datasets and drug-target annotations can potentially be useful as a screening tool for diseases that lack an accepted cellular model for in vitro screening.
KeywordsAtherosclerosis Gene expression analysis Drug repositioning Bioinformatics
This work was supported by the US National Institutes of Health (award HL098807 to S.A.R.), the Medical Research Foundation of Oregon (New Investigator Grant award to S.A.R.), Oregon State University (Division of Health Sciences Interdisciplinary Research Grant award to S.A.R. and University Honors College DeLoach Work Scholarship to A.Y.), the National Science Foundation (award numbers 1557605-DMS and 1553728-DBI to S.A.R.), and the Oregon State University Center for Genome Research and Biocomputing.
- 3.Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z (2015) A survey of current trends in computational drug repurposing. Brief Bioinform (ePub ahead of print)Google Scholar
- 9.Benjamini Y, Hochberg Y (1994) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57(1):289–300Google Scholar
- 12.Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289CrossRefPubMedGoogle Scholar
- 21.Bowes AJ, Khan MI, Shi Y, Robertson L, Werstuck GH (2009) Valproate attenuates accelerated atherosclerosis in hyperglycemic apoE-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis. Am J Pathol 174:330–342CrossRefPubMedPubMedCentralGoogle Scholar